Trial reportBMC infectious diseases2025
A randomized, non-inferiority phase III clinical trial of immunogenicity and safety of 5-dose and 4-dose schedules of a freeze-dried human rabies vaccine (MRC-5 cells) in participants aged 10-60.
Trial report in BMC infectious diseases, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06078423 (Randomized, Blind, Phase III Clinical Trial Comparing the Immunogenicity and Safety of Freeze-dried Human Rabies Vaccine), which is not on this map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Randomized, Blind, Phase III Clinical Trial Comparing the Immunogenicity and Safety of Freeze-dried Human Rabies Vaccine (MRC-5 Cells) With a 5-dose Program and a 4-dose (2-dose First-dose) Program
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThis study aimed to evaluate the safety and immunogenicity of 5-dose and 4-dose schedules of a freeze-dried human rabies vaccine (MRC-5 cells) in participants aged 10–60
methodsThis study adopts a randomized, double-masked, single-center, non-inferiority trial design with similar vaccines. This phase III clinical trial consisted of two stages, the first stage recruited 80 participants, and the second stage recruited 1,800 participants. In stage 1, 40 participants aged 18–60 years were enrolled to vaccinate with the investigational vaccine firstly, and then 40 people aged 10–17 years were enrolled for safety analysis. The number of participants who received either a 5-dose or a 4-dose immunization regimen was 40. During stage 2, subjects were assigned to 5-dose Essen group, 4-dose Zagreb group, 5-dose control group to conduct rabies virus neutralization antibody detection and adverse events(AEs) collection.
resultsIn stage 2, 14 days after the initial dose of immunization and 14 days after completing the immunization program, the differences in the seroconversion rates (5-dose Essen group vs. 5-dose control group, 4-dose Zagreb group vs. 5-dose control group) were both 0.00, with the lower limits of the 95% confidence intervals exceeding the non-inferiority margin of −5%. AEs occurred at a total rate of 35.17% in the 5-dose Essen group, 36.50% in the 5-dose control group, and 30.00% in the 4-dose Zagreb group.
conclusionsThe immunogenicity of 5-dose and 4-dose schedules of the freeze-dried human rabies vaccine (MRC-5 cells) was non-inferior to that of the human diploid cell vaccine, and the safety was good after vaccination. TRIALS REGISTRATION: NCT06078423, A Clinical Trial of Freeze-dried Human Rabies Vaccine (MRC-5 Cells), “retrospectively registered” on 2023–10-11.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.